<DOC>
	<DOCNO>NCT01674036</DOCNO>
	<brief_summary>The objective study assess tolerability , safety pharmacokinetic parameter Genz-682452 healthy adult male , two part . Part 1 ( GZFD00111TDU12766 ) : double-blind , randomize , placebo-controlled , sequential ascend single dose study ; Part 2 ( GZFD00211FED12767 ) : open-label , randomize , 2-sequence , 2-period , 2-treatment crossover study minimum wash-out period ; obtain preliminary information pharmacokinetics , tolerability safety Genz-682452 single oral dos feed fasted condition . Subjects allow participate 1 part study .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Genz-682452 Healthy Men</brief_title>
	<detailed_description />
	<criteria>Body weight 50.0 100.0 kg , inclusive , body mass index 18.0 32.0 kg/m^2 , inclusive . Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) . Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , infectious disease , sign acute illness . Frequent headache and/or migraine , recurrent nausea and/or vomit . Blood donation , great 100 mL , within 2 month inclusion . Presence history drug hypersensitivity , allergic disease diagnose treated physician . History presence drug alcohol abuse . Unable stop smoking cigarette study . Excessive consumption beverage contain xanthine base .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>